Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy

Michel Clavel, Silvio Monfardini, Stein Gundersen, Stanley Kaye, Pierre Siegenthaler, Josette Renard, Martine Van Glabbeke, Herbert M. Pinedo

Research output: Contribution to journalArticle


Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks. All the patients progressed or recurred after chemotherapy including cisplatin. The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively. Nausea and vomiting were almost universal but mild in intensity. One renal failure occurred 6 weeks after the first cycle while the tumor was progressing. No antitumor activity was observed in this heavily pretreated population of patients.

Original languageEnglish (US)
Pages (from-to)1345-1348
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number8
Publication statusPublished - 1988
Externally publishedYes


ASJC Scopus subject areas

  • Oncology

Cite this